Invention:
This technology includes several SNP (single nucleotide polymorphism) markers with high potential of clinical utility to identify patients that will develop locally advanced stages of prostate cancer.
Background:
The worldwide elderly population is experiencing an increase in prostate cancer. For prostate cancer prognosis, PSA levels and biopsy are sometimes inconclusive, leaving doctors and patients a difficult decision on whether to do a prostatectomy or not. These SNP markers (related to microRNA splicing) identified by the inventing team will help them to make a more informative decision.
Applications:
- Clinical prognosis markers to predict aggressive prostate cancer
- Can also be used to predict worse prognosis for breast cancer
Advantages:
- Provides strong biomarkers to predict a patient’s risk on developing aggressive prostate cancer
- Aids in improving decision making for treatment options
Status: issued U.S. patent #11,692,226
